Last Updated: November 16, 2026

Investigational Drug Information for BIIB074

« Back to Dashboard


What is the development status for investigational drug BIIB074?

BIIB074 is an investigational drug.

There have been 18 clinical trials for BIIB074. The most recent clinical trial was a Phase 2 trial, which was initiated on April 19th 2023.

The most common disease conditions in clinical trials are Neuralgia, Trigeminal Neuralgia, and Bipolar Disorder. The leading clinical trial sponsors are Biogen, GlaxoSmithKline, and Convergence Pharmaceuticals.

There are seventy-eight US patents protecting this investigational drug and four hundred and eighteen international patents.

Recent Clinical Trials for BIIB074
TitleSponsorPhase
802NP301 Efficacy and Safety Study of BIIB074 in Participants With Trigeminal NeuralgiaBiogenPhase 3
802NP302 Efficacy and Safety Study of BIIB074 in Participants With Trigeminal NeuralgiaBiogenPhase 3
Pharmacodynamic Study of BIIB095 and BIIB074 in Healthy Participants and Participants With Painful Diabetic PolyneuropathyBiogenPhase 1

See all BIIB074 clinical trials

Clinical Trial Summary for BIIB074

Top disease conditions for BIIB074
Top clinical trial sponsors for BIIB074

See all BIIB074 clinical trials

US Patents for BIIB074

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
BIIB074 ⤷  Start Trial Pyridone amides as modulators of sodium channels VERTEX PHARMACEUTICALS INCORPORATED (Boston, MA) ⤷  Start Trial
BIIB074 ⤷  Start Trial Controlled release dosage form TRIASTEK, INC. (Nanjing, CN) ⤷  Start Trial
BIIB074 ⤷  Start Trial Methods and compositions for decreasing gastric emptying Purdue Pharma L.P. (Stamford, CT) ⤷  Start Trial
BIIB074 ⤷  Start Trial Erythromelalgia treatment Convergence Pharmaceuticals Limited (Maidenhead, GB) ⤷  Start Trial
BIIB074 ⤷  Start Trial Prodrugs of pyridone amides useful as modulators of sodium channels VERTEX PHARMACEUTICALS INCORPORATED (Boston, MA) ⤷  Start Trial
BIIB074 ⤷  Start Trial Process for preparing alpha-carboxamide pyrrolidine derivatives Convergence Pharmaceuticals Limited (GB) ⤷  Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for BIIB074

Drugname Country Document Number Estimated Expiration Related US Patent
BIIB074 Argentina AR094667 2033-01-31 ⤷  Start Trial
BIIB074 Australia AU2014212509 2033-01-31 ⤷  Start Trial
BIIB074 Australia AU2018214105 2033-01-31 ⤷  Start Trial
BIIB074 Australia AU2020204425 2033-01-31 ⤷  Start Trial
BIIB074 Brazil BR112015018289 2033-01-31 ⤷  Start Trial
BIIB074 Canada CA2898866 2033-01-31 ⤷  Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.